 George Wang
Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cannabis | 29 | 2025 | 494 | 7.070 |
Why?
| | Poison Control Centers | 12 | 2022 | 90 | 4.550 |
Why?
| | Drug Overdose | 9 | 2022 | 347 | 3.310 |
Why?
| | Legislation, Drug | 7 | 2021 | 80 | 2.870 |
Why?
| | Medical Marijuana | 5 | 2022 | 117 | 2.690 |
Why?
| | Hallucinogens | 6 | 2024 | 105 | 2.520 |
Why?
| | Marijuana Use | 5 | 2019 | 206 | 2.360 |
Why?
| | Marijuana Smoking | 9 | 2024 | 252 | 2.230 |
Why?
| | Marijuana Abuse | 5 | 2024 | 233 | 2.170 |
Why?
| | Dronabinol | 12 | 2025 | 226 | 2.160 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1000 | 2.030 |
Why?
| | Poisoning | 8 | 2025 | 120 | 1.980 |
Why?
| | Emergency Service, Hospital | 15 | 2021 | 2069 | 1.810 |
Why?
| | Hospitals, Pediatric | 9 | 2022 | 508 | 1.770 |
Why?
| | Cannabinoids | 6 | 2023 | 161 | 1.730 |
Why?
| | Nonprescription Drugs | 4 | 2022 | 63 | 1.660 |
Why?
| | Drug Packaging | 3 | 2018 | 45 | 1.620 |
Why?
| | Diphenhydramine | 6 | 2022 | 37 | 1.560 |
Why?
| | Poisons | 2 | 2022 | 23 | 1.490 |
Why?
| | Hypotension | 4 | 2022 | 122 | 1.410 |
Why?
| | Cough | 3 | 2022 | 122 | 1.410 |
Why?
| | Vomiting | 3 | 2021 | 130 | 1.360 |
Why?
| | Eating | 7 | 2023 | 380 | 1.310 |
Why?
| | Substance-Related Disorders | 4 | 2019 | 1083 | 1.240 |
Why?
| | Child | 37 | 2025 | 21935 | 1.160 |
Why?
| | Substance Abuse Detection | 5 | 2024 | 87 | 1.160 |
Why?
| | Prescription Drugs | 2 | 2020 | 109 | 1.070 |
Why?
| | Epilepsy | 3 | 2020 | 333 | 1.070 |
Why?
| | Child, Preschool | 25 | 2025 | 11074 | 1.070 |
Why?
| | Humans | 85 | 2025 | 137585 | 1.020 |
Why?
| | Antitussive Agents | 3 | 2021 | 7 | 1.010 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2022 | 125 | 1.010 |
Why?
| | Medication Errors | 2 | 2019 | 95 | 0.980 |
Why?
| | Colorado | 16 | 2023 | 4565 | 0.950 |
Why?
| | Infant | 22 | 2025 | 9465 | 0.930 |
Why?
| | Adolescent | 30 | 2025 | 21513 | 0.930 |
Why?
| | Muscarinic Antagonists | 2 | 2022 | 29 | 0.890 |
Why?
| | Dextromethorphan | 3 | 2021 | 18 | 0.860 |
Why?
| | Oxycodone | 2 | 2021 | 42 | 0.860 |
Why?
| | Eyelids | 1 | 2024 | 37 | 0.850 |
Why?
| | Multi-Ingredient Cold, Flu, and Allergy Medications | 2 | 2020 | 2 | 0.830 |
Why?
| | Fentanyl | 2 | 2021 | 94 | 0.820 |
Why?
| | Ambulatory Care | 4 | 2021 | 546 | 0.800 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2022 | 250 | 0.790 |
Why?
| | Phytotherapy | 2 | 2013 | 83 | 0.780 |
Why?
| | Psychotropic Drugs | 2 | 2021 | 68 | 0.780 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2022 | 14 | 0.760 |
Why?
| | Fractures, Closed | 1 | 2022 | 17 | 0.760 |
Why?
| | Cannabidiol | 2 | 2022 | 119 | 0.740 |
Why?
| | Retrospective Studies | 20 | 2022 | 15657 | 0.730 |
Why?
| | Female | 43 | 2025 | 73304 | 0.720 |
Why?
| | Bupropion | 1 | 2021 | 45 | 0.710 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 116 | 0.710 |
Why?
| | Physostigmine | 1 | 2020 | 12 | 0.700 |
Why?
| | Akathisia, Drug-Induced | 1 | 2020 | 6 | 0.700 |
Why?
| | Lorazepam | 1 | 2020 | 27 | 0.690 |
Why?
| | Acute Pain | 1 | 2021 | 50 | 0.690 |
Why?
| | United States | 17 | 2024 | 14841 | 0.690 |
Why?
| | Anesthesia | 1 | 2023 | 189 | 0.680 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 333 | 0.660 |
Why?
| | Clenbuterol | 1 | 2019 | 4 | 0.650 |
Why?
| | Common Cold | 1 | 2019 | 13 | 0.640 |
Why?
| | Psychotic Disorders | 1 | 2022 | 170 | 0.640 |
Why?
| | Male | 36 | 2025 | 67762 | 0.640 |
Why?
| | Black Widow Spider | 1 | 2019 | 9 | 0.640 |
Why?
| | Spider Venoms | 1 | 2019 | 11 | 0.640 |
Why?
| | Delirium | 1 | 2020 | 92 | 0.630 |
Why?
| | Designer Drugs | 1 | 2019 | 8 | 0.620 |
Why?
| | Bradycardia | 2 | 2023 | 55 | 0.610 |
Why?
| | Biguanides | 1 | 2018 | 12 | 0.590 |
Why?
| | Plant Extracts | 1 | 2020 | 202 | 0.580 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 1 | 2018 | 11 | 0.580 |
Why?
| | Anticonvulsants | 1 | 2020 | 217 | 0.580 |
Why?
| | Face | 1 | 2019 | 173 | 0.570 |
Why?
| | Schizophrenia | 1 | 2022 | 439 | 0.560 |
Why?
| | Capsaicin | 1 | 2017 | 26 | 0.560 |
Why?
| | Child Abuse | 2 | 2022 | 535 | 0.560 |
Why?
| | Tertiary Care Centers | 2 | 2017 | 160 | 0.560 |
Why?
| | Mass Spectrometry | 1 | 2021 | 739 | 0.560 |
Why?
| | Antiemetics | 1 | 2017 | 43 | 0.540 |
Why?
| | Accidents, Home | 1 | 2017 | 31 | 0.540 |
Why?
| | Tachycardia | 2 | 2019 | 57 | 0.540 |
Why?
| | Drug Storage | 1 | 2017 | 57 | 0.530 |
Why?
| | Emergency Services, Psychiatric | 1 | 2017 | 31 | 0.530 |
Why?
| | Acetaminophen | 3 | 2022 | 268 | 0.520 |
Why?
| | Emergency Medicine | 1 | 2019 | 226 | 0.520 |
Why?
| | Fractures, Bone | 1 | 2021 | 380 | 0.520 |
Why?
| | Acetylcysteine | 2 | 2022 | 145 | 0.510 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 28 | 0.510 |
Why?
| | Renal Insufficiency | 1 | 2018 | 162 | 0.500 |
Why?
| | Buprenorphine | 1 | 2020 | 173 | 0.500 |
Why?
| | Narcotic Antagonists | 1 | 2018 | 181 | 0.500 |
Why?
| | Hyperammonemia | 1 | 2015 | 16 | 0.480 |
Why?
| | Seizures | 1 | 2019 | 426 | 0.470 |
Why?
| | Methanol | 1 | 2015 | 38 | 0.470 |
Why?
| | Food | 1 | 2016 | 164 | 0.460 |
Why?
| | Hospitalization | 3 | 2022 | 2199 | 0.450 |
Why?
| | Metformin | 1 | 2018 | 331 | 0.450 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 261 | 0.440 |
Why?
| | Toxicology | 1 | 2015 | 48 | 0.440 |
Why?
| | Electrocardiography | 2 | 2019 | 629 | 0.440 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.420 |
Why?
| | Students | 1 | 2019 | 622 | 0.410 |
Why?
| | Accidents | 1 | 2013 | 37 | 0.410 |
Why?
| | Plant Preparations | 1 | 2013 | 36 | 0.410 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.410 |
Why?
| | Amphotericin B | 1 | 2013 | 31 | 0.400 |
Why?
| | Risk Assessment | 3 | 2017 | 3457 | 0.400 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.400 |
Why?
| | Flecainide | 1 | 2012 | 7 | 0.390 |
Why?
| | Asymptomatic Diseases | 1 | 2013 | 89 | 0.390 |
Why?
| | Antifungal Agents | 1 | 2013 | 136 | 0.380 |
Why?
| | Adult | 14 | 2024 | 37929 | 0.380 |
Why?
| | Pharmacy | 1 | 2012 | 32 | 0.370 |
Why?
| | Drug Compounding | 1 | 2012 | 101 | 0.370 |
Why?
| | Tertiary Healthcare | 2 | 2021 | 33 | 0.370 |
Why?
| | Acid-Base Equilibrium | 2 | 2022 | 28 | 0.370 |
Why?
| | Tremor | 2 | 2024 | 65 | 0.360 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 88 | 0.350 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 30 | 0.350 |
Why?
| | Hospital Rapid Response Team | 1 | 2010 | 19 | 0.340 |
Why?
| | Cannabinoid Receptor Agonists | 4 | 2023 | 46 | 0.340 |
Why?
| | Referral and Consultation | 2 | 2021 | 786 | 0.340 |
Why?
| | Health Facilities | 2 | 2022 | 84 | 0.340 |
Why?
| | Liver Failure | 1 | 2011 | 94 | 0.330 |
Why?
| | Antidotes | 2 | 2022 | 143 | 0.330 |
Why?
| | Antivenins | 2 | 2020 | 36 | 0.330 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 806 | 0.330 |
Why?
| | Population Surveillance | 1 | 2013 | 482 | 0.330 |
Why?
| | Practice Patterns, Physicians' | 4 | 2023 | 1313 | 0.330 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1291 | 0.310 |
Why?
| | Acidosis | 2 | 2021 | 101 | 0.300 |
Why?
| | Pediatrics | 2 | 2017 | 1101 | 0.280 |
Why?
| | Suicide, Attempted | 1 | 2011 | 378 | 0.270 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 641 | 0.270 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2025 | 301 | 0.270 |
Why?
| | Tandem Mass Spectrometry | 3 | 2022 | 532 | 0.260 |
Why?
| | Incidence | 3 | 2021 | 2804 | 0.250 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.240 |
Why?
| | Half-Life | 2 | 2019 | 164 | 0.240 |
Why?
| | Young Adult | 7 | 2024 | 13209 | 0.240 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 5472 | 0.230 |
Why?
| | Public Health | 4 | 2025 | 588 | 0.230 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2531 | 0.210 |
Why?
| | Analgesics | 2 | 2023 | 206 | 0.210 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2019 | 233 | 0.210 |
Why?
| | Shock | 1 | 2025 | 98 | 0.210 |
Why?
| | Hemodiafiltration | 1 | 2022 | 9 | 0.190 |
Why?
| | Case-Control Studies | 2 | 2022 | 3556 | 0.190 |
Why?
| | Research Design | 2 | 2025 | 1139 | 0.190 |
Why?
| | Prescriptions | 1 | 2021 | 67 | 0.180 |
Why?
| | Infant, Newborn | 3 | 2021 | 6079 | 0.180 |
Why?
| | Prevalence | 2 | 2019 | 2734 | 0.170 |
Why?
| | Infusions, Intravenous | 2 | 2013 | 413 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 249 | 0.170 |
Why?
| | Snake Bites | 1 | 2020 | 29 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2024 | 2057 | 0.170 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2020 | 59 | 0.170 |
Why?
| | Syndrome | 1 | 2021 | 358 | 0.170 |
Why?
| | Databases, Factual | 3 | 2021 | 1357 | 0.170 |
Why?
| | Length of Stay | 3 | 2021 | 1215 | 0.170 |
Why?
| | Anti-Anxiety Agents | 1 | 2020 | 46 | 0.170 |
Why?
| | Hospitals | 2 | 2023 | 691 | 0.170 |
Why?
| | Heart Rate | 1 | 2024 | 822 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2022 | 245 | 0.160 |
Why?
| | Flank Pain | 1 | 2019 | 10 | 0.160 |
Why?
| | Performance-Enhancing Substances | 1 | 2019 | 10 | 0.160 |
Why?
| | Heart Arrest | 1 | 2023 | 339 | 0.160 |
Why?
| | Milk, Human | 1 | 2021 | 158 | 0.160 |
Why?
| | Poisson Distribution | 1 | 2019 | 75 | 0.160 |
Why?
| | Public Health Surveillance | 1 | 2019 | 82 | 0.150 |
Why?
| | Cardiotoxicity | 1 | 2019 | 26 | 0.150 |
Why?
| | Temperature | 1 | 2022 | 679 | 0.150 |
Why?
| | Biological Availability | 1 | 2019 | 148 | 0.150 |
Why?
| | Self Report | 2 | 2024 | 827 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2019 | 45 | 0.150 |
Why?
| | Morphine | 1 | 2020 | 158 | 0.150 |
Why?
| | Hyperlactatemia | 1 | 2018 | 3 | 0.150 |
Why?
| | Adrenergic beta-Agonists | 1 | 2019 | 134 | 0.150 |
Why?
| | Epidemics | 1 | 2020 | 89 | 0.150 |
Why?
| | Methadone | 1 | 2020 | 101 | 0.150 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3284 | 0.150 |
Why?
| | Drug Utilization | 1 | 2019 | 169 | 0.150 |
Why?
| | Treatment Outcome | 4 | 2020 | 10811 | 0.150 |
Why?
| | Tissue Distribution | 1 | 2019 | 332 | 0.150 |
Why?
| | Adolescent Health | 1 | 2018 | 39 | 0.140 |
Why?
| | Vulnerable Populations | 1 | 2019 | 163 | 0.140 |
Why?
| | Prospective Studies | 3 | 2021 | 7604 | 0.140 |
Why?
| | Administration, Topical | 1 | 2017 | 151 | 0.140 |
Why?
| | Urine | 1 | 2017 | 59 | 0.140 |
Why?
| | Physical Examination | 1 | 2018 | 241 | 0.130 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 390 | 0.130 |
Why?
| | Health Surveys | 1 | 2019 | 514 | 0.130 |
Why?
| | Risk Factors | 4 | 2017 | 10388 | 0.130 |
Why?
| | Administration, Oral | 1 | 2019 | 816 | 0.130 |
Why?
| | Regression Analysis | 1 | 2019 | 1024 | 0.130 |
Why?
| | Physician's Role | 1 | 2018 | 211 | 0.130 |
Why?
| | Preventive Health Services | 1 | 2018 | 148 | 0.130 |
Why?
| | Pregnancy | 2 | 2022 | 6763 | 0.130 |
Why?
| | Universities | 1 | 2019 | 433 | 0.130 |
Why?
| | Pain Management | 1 | 2019 | 352 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 530 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 212 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2020 | 1993 | 0.120 |
Why?
| | Tea Tree Oil | 1 | 2015 | 2 | 0.120 |
Why?
| | Middle Aged | 5 | 2024 | 33479 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 248 | 0.110 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 92 | 0.110 |
Why?
| | Glasgow Coma Scale | 1 | 2015 | 186 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2015 | 303 | 0.110 |
Why?
| | Parents | 2 | 2021 | 1347 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 96 | 0.110 |
Why?
| | Pulmonary Surfactants | 1 | 2015 | 106 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1070 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 4 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 28 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 548 | 0.100 |
Why?
| | Clinical Enzyme Tests | 1 | 2013 | 11 | 0.100 |
Why?
| | Salicylates | 1 | 2013 | 28 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.100 |
Why?
| | Spasm | 1 | 2013 | 20 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2018 | 530 | 0.100 |
Why?
| | Urinalysis | 1 | 2013 | 77 | 0.100 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2013 | 45 | 0.100 |
Why?
| | Blood Chemical Analysis | 1 | 2013 | 99 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 332 | 0.100 |
Why?
| | Mycoses | 1 | 2013 | 79 | 0.100 |
Why?
| | Osmolar Concentration | 2 | 2022 | 171 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 343 | 0.090 |
Why?
| | Cohort Studies | 1 | 2022 | 5742 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 318 | 0.090 |
Why?
| | Medical Audit | 1 | 2011 | 78 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 202 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 21 | 0.090 |
Why?
| | International Normalized Ratio | 1 | 2011 | 47 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1483 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 114 | 0.090 |
Why?
| | Kidney | 1 | 2018 | 1468 | 0.080 |
Why?
| | Alanine Transaminase | 1 | 2011 | 157 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 515 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 85 | 0.080 |
Why?
| | Mass Screening | 1 | 2018 | 1287 | 0.080 |
Why?
| | Age Factors | 1 | 2017 | 3295 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 6828 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 435 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 786 | 0.080 |
Why?
| | Survival Rate | 1 | 2013 | 1972 | 0.070 |
Why?
| | Mental Disorders | 1 | 2017 | 1077 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1050 | 0.070 |
Why?
| | Suicide | 1 | 2015 | 656 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 2295 | 0.070 |
Why?
| | Primary Health Care | 1 | 2018 | 1738 | 0.070 |
Why?
| | Pain | 1 | 2013 | 756 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5778 | 0.060 |
Why?
| | Animals | 3 | 2020 | 36940 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 708 | 0.060 |
Why?
| | Depression | 1 | 2015 | 1397 | 0.060 |
Why?
| | Emergency Medical Services | 1 | 2011 | 552 | 0.060 |
Why?
| | Digoxin | 1 | 2023 | 31 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 688 | 0.050 |
Why?
| | Toxicokinetics | 1 | 2022 | 9 | 0.050 |
Why?
| | Benzodiazepines | 1 | 2023 | 155 | 0.050 |
Why?
| | Brompheniramine | 1 | 2021 | 2 | 0.050 |
Why?
| | Doxylamine | 1 | 2021 | 2 | 0.050 |
Why?
| | Guaifenesin | 1 | 2021 | 2 | 0.050 |
Why?
| | Pseudoephedrine | 1 | 2021 | 2 | 0.050 |
Why?
| | Chlorpheniramine | 1 | 2021 | 5 | 0.050 |
Why?
| | Valproic Acid | 1 | 2022 | 48 | 0.050 |
Why?
| | American Heart Association | 1 | 2023 | 306 | 0.050 |
Why?
| | Phenylephrine | 1 | 2021 | 75 | 0.050 |
Why?
| | Drug Labeling | 1 | 2021 | 39 | 0.050 |
Why?
| | Vasodilation | 1 | 2025 | 499 | 0.040 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2023 | 323 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2010 | 5131 | 0.040 |
Why?
| | Homicide | 1 | 2021 | 69 | 0.040 |
Why?
| | Crotalus | 1 | 2020 | 26 | 0.040 |
Why?
| | Crotalid Venoms | 1 | 2020 | 31 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2023 | 279 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 433 | 0.040 |
Why?
| | Health Care Costs | 1 | 2021 | 398 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 23 | 0.040 |
Why?
| | Models, Biological | 1 | 2024 | 1783 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 597 | 0.030 |
Why?
| | Safety | 1 | 2017 | 338 | 0.030 |
Why?
| | Deglutition | 1 | 2015 | 72 | 0.030 |
Why?
| | Registries | 1 | 2021 | 2035 | 0.030 |
Why?
| | Biomarkers | 1 | 2023 | 4149 | 0.020 |
Why?
|
|
Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|